Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Purchased by Blair William & Co. IL

Blair William & Co. IL grew its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 8.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,199 shares of the company’s stock after purchasing an additional 913 shares during the period. Blair William & Co. IL’s holdings in Takeda Pharmaceutical were worth $162,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Summit Global Investments boosted its position in Takeda Pharmaceutical by 75.5% during the fourth quarter. Summit Global Investments now owns 729,200 shares of the company’s stock worth $9,655,000 after acquiring an additional 313,642 shares during the last quarter. FMR LLC boosted its holdings in shares of Takeda Pharmaceutical by 10.9% during the third quarter. FMR LLC now owns 2,908,918 shares of the company’s stock worth $41,365,000 after purchasing an additional 286,052 shares during the last quarter. Stifel Financial Corp grew its position in shares of Takeda Pharmaceutical by 103.9% in the third quarter. Stifel Financial Corp now owns 440,666 shares of the company’s stock valued at $6,266,000 after purchasing an additional 224,594 shares during the period. Crossmark Global Holdings Inc. increased its stake in Takeda Pharmaceutical by 284.9% in the fourth quarter. Crossmark Global Holdings Inc. now owns 210,484 shares of the company’s stock valued at $2,787,000 after purchasing an additional 155,795 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Takeda Pharmaceutical during the fourth quarter worth about $1,447,000. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Stock Performance

NYSE:TAK opened at $14.74 on Monday. The company has a market cap of $46.89 billion, a P/E ratio of 36.84, a P/E/G ratio of 0.24 and a beta of 0.39. The firm’s 50 day moving average is $14.35 and its two-hundred day moving average is $13.92. Takeda Pharmaceutical Company Limited has a fifty-two week low of $12.58 and a fifty-two week high of $15.37. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63.

Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Analyst Ratings Changes

Separately, Morgan Stanley raised shares of Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.